Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels. - Wikidata - wikimedia - TriplyDB

Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels.

Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels.

http://www.wikidata.org/entity/Q33577851

about

PCSK9 and triglyceride-rich lipoprotein metabolism Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease.High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans.Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs.Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9).Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents.Proprotein convertase subtilisin/kexin type 9 expression is transiently up-regulated in the acute period of myocardial infarction in rat.Peroxisome Proliferator-activated receptor γ activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression Furin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels.Switching statin-treated patients from fenofibrate to the prescription omega-3 therapy icosapent ethyl: a retrospective case series.Correlation between serum levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) and atherogenic lipoproteins in patients with coronary artery disease The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications.Proprotein convertase subtilisin/kexin type 9: a new target molecule for gene therapy.Evaluation of proprotein convertase subtilisin/kexin type 9: focus on potential clinical and therapeutic implications for low-density lipoprotein cholesterol lowering.Lipid Lowering Therapy and Circulating PCSK9 Concentration.Proprotein convertase subtilisin / kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015).PPAR-α agonists are still on the rise: an update on clinical and experimental findings.PCSK9 Inhibitors: Treating the Right Patients in Daily Practice.Short- and long-term effects of xuezhikang, an extract of cholestin, on serum proprotein convertase subtilisin/kexin type 9 levels.PCSK9 Mutations in Familial Hypercholesterolemia: from a Groundbreaking Discovery to Anti-PCSK9 Therapies.PCSK9 in diabetic kidney disease.

P2860

Q26796287-7E2C2C91-76A4-4E61-AB66-91EC1F26CDC9 Q33599961-85BCC3AE-3900-415E-AA9C-96AEED2BA79E Q34053143-A49BF825-6FF2-436D-907C-C72E95B4C93E Q34188114-4BED9C4C-69A0-476D-8499-BB1400AA45B3 Q34430377-A15517F9-C771-479D-BCF4-63776F3585B0 Q34458693-BB8C21A4-82B4-4292-8589-F76FA335DD24 Q34662589-4FC54BFC-A01B-4967-A2B8-C756A629EF66 Q34789111-05D3686B-B666-416E-A89F-E976DA919A0D Q36078804-299953A5-772A-4CAC-B56C-F72E37BD15C3 Q36481769-A8A31BEB-34D6-4CF3-B922-A8795EB19AE4 Q36712679-CA37C68A-AEDA-45E9-9C1A-6309623B2F30 Q37278608-C2D247DD-07EA-42EB-865D-C58C32CF812F Q37880856-1AB0B1F6-EF0F-425D-A01A-2D9C4A597932 Q37981958-33B2C321-54D8-457F-9D27-0C71D78D45B2 Q38095872-74A390FF-7B64-4FB6-84A9-963E6DD0D892 Q38643197-CB894D20-412D-439C-B4AB-87CE8BCB82A8 Q38846832-BB129DE8-8914-4E3B-9074-3DB4491C54BB Q39200940-C0024E8E-4BC1-45A1-B841-929521BD07D8 Q39393317-BEC88475-54ED-4582-B69F-0CD8F592D437 Q44496513-6BE39D06-A6DD-4B1A-B08A-77F7B2871E3D Q47567094-88D019DD-FFD7-4A9D-A72A-4B7030E7A7A6 Q51628723-F8795235-2008-446C-907F-990D6F5B1FFD

P2860

Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels.

http://www.wikidata.org/entity/Q33577851

description

2009 nî lūn-bûn

@nan

2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Fenofibrate treatment increase ...... ubtilisin kexin type 9 levels.

@ast

Fenofibrate treatment increase ...... ubtilisin kexin type 9 levels.

@en

Fenofibrate treatment increase ...... ubtilisin kexin type 9 levels.

@nl

type

label

Fenofibrate treatment increase ...... ubtilisin kexin type 9 levels.

@ast

Fenofibrate treatment increase ...... ubtilisin kexin type 9 levels.

@en

Fenofibrate treatment increase ...... ubtilisin kexin type 9 levels.

@nl

prefLabel

Fenofibrate treatment increase ...... ubtilisin kexin type 9 levels.

@ast

Fenofibrate treatment increase ...... ubtilisin kexin type 9 levels.

@en

Fenofibrate treatment increase ...... ubtilisin kexin type 9 levels.

@nl

P1433

Q33577851-EF5A19B6-8DB9-40EE-91B2-6B8E74171388

P1476

Q33577851-05BDD408-BBDF-4F6F-903C-270F6B25A45C

P2093

Q33577851-0FC26FE0-2BD7-4C59-A87D-7B56D0EFAA1A

Q33577851-64D9CF3C-17F7-451B-B34B-4F267C34973D

Q33577851-CE574631-FF43-4494-8E2B-1CDABD6B16E0

Q33577851-EF6EE788-54BC-4587-9578-87AABC5A73BE

P2860

Q33577851-07418A13-8586-46F1-BB47-DC60003D08D3

Q33577851-0A470CBF-624F-467C-8731-C2EBFAF83A21

Q33577851-16B557F2-EE9E-4DDB-80BD-26D75407A275

Q33577851-175B6065-8170-4185-BF8E-3B1A0AF2CFE3

Q33577851-1F43EFE9-7490-4B28-909E-FD87BA8C5154

Q33577851-2374D0AE-C36E-4B48-BDA4-CE3AFCC1034B

Q33577851-270D9A57-74DB-465F-BBF0-CB8CB7463189

Q33577851-37F333A9-6256-4527-80EC-C8CDDECFA844

Q33577851-3CDF594F-BF32-423C-85E2-55585674F119

Q33577851-3D079846-C39C-4D85-830E-2B62366D49E1

P304

Q33577851-2A6BD83C-DDEB-4842-9BCA-A0E0A06D9186

P31

Q33577851-6F06B498-5CFF-40AF-9835-5323F437CF78

P356

Q33577851-7496463B-90F9-4118-8DAB-3BB49FC8F16B

P433

Q33577851-D03388DF-67A8-4C2C-BA05-143DE737B605

P478

Q33577851-C201957B-0BC4-4FE5-814E-1BE1EDD54BAA

P577

Q33577851-678A10E9-EA69-4F3B-9704-8F83A1AAFBF7

P698

Q33577851-FDEF41FD-EA6B-4B71-868E-497961180EB4

P932

Q33577851-35E4F0A5-1D23-4B63-952E-565FB5047B1B

P356

P1433

Journal of Lipid Research

P1476

Fenofibrate treatment increase ...... ubtilisin kexin type 9 levels.

@en

P2093

Guoqing Cao

http://www.w3.org/2001/XMLSchema#string

Jason S Troutt

http://www.w3.org/2001/XMLSchema#string

Robert J Konrad

http://www.w3.org/2001/XMLSchema#string

William E Alborn

http://www.w3.org/2001/XMLSchema#string

P2860

Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation

Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice

A novel loss of function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol

Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype

Molecular biology of PCSK9: its role in LDL metabolism

Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 Cells

A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells

Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9

P304

345-351

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1194/JLR.M000620

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

51

http://www.w3.org/2001/XMLSchema#string

P577

2009-09-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19738285

http://www.w3.org/2001/XMLSchema#string

P932

2803236

http://www.w3.org/2001/XMLSchema#string